Screener
Xenon Pharmaceuticals XENE EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The source filing: Xenon Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338244
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Net loss | $(110,736) | $(84,706) | $(213,038) | $(149,753) |
| Other comprehensive income (loss): | ||||
| Unrealized gain (loss) on available-for-sale securities (note 5) | (1,445) | 949 | (2,991) | 1,725 |
| Comprehensive loss | $(112,181) | $(83,757) | $(216,029) | $(148,028) |
| Net loss per common share (note 10): | ||||
| Basic and diluted | $(1.11) | $(1.07) | $(2.28) | $(1.90) |
| Weighted-average common shares outstanding (note 10): | ||||
| Basic and diluted | 99,609,804 | 78,953,445 | 93,477,761 | 78,820,474 |
Item 1. Financial Statements
FAQ
- What is Xenon Pharmaceuticals's EPS (basic)?
- Xenon Pharmaceuticals (XENE) reported EPS (basic) of -$1.11 in Q2 2026.
- How has Xenon Pharmaceuticals's EPS (basic) changed year-over-year?
- Xenon Pharmaceuticals's EPS (basic) decreased by 3.7% year-over-year, from -$1.07 to -$1.11.
- What is the long-term trend for Xenon Pharmaceuticals's EPS (basic)?
- Over 4 years (2021 to 2025), Xenon Pharmaceuticals's EPS (basic) has grown at a 25.3% compound annual growth rate (CAGR), from -$1.77 to -$4.36.
- What does EPS (basic) mean?
- Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.
Ask your AI about Xenon Pharmaceuticals's eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude